Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/120679
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Immunogenicity and safety of a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine 6 years after MenC priming as toddlers |
Author: | Nolan, T. Booy, R. Marshall, H.S. Richmond, P. Nissen, M. Ziegler, J.B. Baine, Y. Traskine, M. Jastorff, A. Van der Wielen, M. |
Citation: | The Pediatric Infectious Disease Journal, 2019; 38(6):643-650 |
Publisher: | Lippincott Williams & Wilkins |
Issue Date: | 2019 |
ISSN: | 0891-3668 1532-0987 |
Statement of Responsibility: | Terry Nolan, Robert Booy, Helen Marshall, Peter Richmond, Michael Nissen, John Ziegler, Yaela Baine, Magali Traskine, Archana Jastorf, Marie Van der Wielen |
Abstract: | BACKGROUND:We assessed immunogenicity, antibody persistence and safety of the meningococcal serogroups A, C, W and Y-tetanus toxoid (TT) conjugate vaccine (MenACWY-TT) in children primed as toddlers with MenC vaccine. METHODS:This open, multicenter extension study enrolled children 84-95 months of age who had received one dose of the combined Haemophilus influenzae type b (Hib)-MenC-TT conjugate vaccine (HibMenC group) or Hib-TT and monovalent MenC (MCC)-CRM197 vaccines (Hib+MCC group) at 12-18 months of age, in the primary study. All participants received one dose of MenACWY-TT. We assessed immunogenicity against MenA, MenC, MenW and MenY at 1 month and 2 years postvaccination by serum bactericidal assay using baby rabbit complement (rSBA). Safety and reactogenicity were evaluated. RESULTS:Six years post-MenC vaccination, <20% of children retained rSBA-MenC titers ≥1:8. At 1 month post-MenACWY-TT vaccination, vaccine response rates against all serogroups were high for both groups with ≥97.1% of children having rSBA ≥1:8. Two years postvaccination, ≥63.6% of children retained rSBA-MenA ≥1:8, and ≥87.9% for other serogroups. Geometric mean titers for all serogroups declined at 2 years post-MenACWY-TT vaccination, but remained ≥13 times higher than prevaccination levels. For both groups, pain (≤58.5%), redness (≤51.4%) and fatigue (≤27.0%) were the most frequently reported adverse events. No serious adverse events were reported. CONCLUSIONS:One dose of MenACWY-TT boosts protection against MenC in primed children, is safe and extends protection against MenA, MenW and MenY. Immunogenicity and safety were comparable in infants vaccinated with conjugated vaccine (HibMenC-TT) or the separate vaccines (Hib-TT and MCC-CRM197). |
Keywords: | Quadrivalent meningococcal vaccine; children; bactericidal activity; persistence; safety |
Rights: | © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. |
DOI: | 10.1097/INF.0000000000002334 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1084951 |
Published version: | http://dx.doi.org/10.1097/inf.0000000000002334 |
Appears in Collections: | Aurora harvest 4 Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.